
Nathan B Fountain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8166349/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children. Expert Review of Neurotherapeutics, 2022, 22, 1-13.	2.8	1
2	Impact of the COVID-19 Pandemic on Epilepsy Center Practice in the United States. Neurology, 2022, 98, .	1.1	18
3	United States Epilepsy Center Characteristics. Neurology, 2022, 98, .	1.1	28
4	Considerations for determining the efficacy of new antiseizure medications in children age 1Âmonth to younger than 2 years. Epilepsia, 2022, 63, 2664-2670.	5.1	4
5	Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After Highâ€Dose Intravenous Administration in Young Children With Benzodiazepineâ€Refractory Status Epilepticus. Journal of Clinical Pharmacology, 2021, 61, 763-768.	2.0	3
6	Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. Epilepsia, 2021, 62, 795-806.	5.1	39
7	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. JAMA Neurology, 2021, 78, 285.	9.0	139
8	Diverse genetic causes of polymicrogyria with epilepsy. Epilepsia, 2021, 62, 973-983.	5.1	12
9	The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia, 2020, 61, e66-e70.	5.1	8
10	Electrocorticographic events from long-term ambulatory brain recordings can potentially supplement seizure diaries. Epilepsy Research, 2020, 161, 106302.	1.6	30
11	Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet, The, 2020, 395, 1217-1224.	13.7	143
12	Incidence of seizure exacerbation and injury related to football participation in people with epilepsy. Epilepsy and Behavior, 2020, 104, 106888.	1.7	3
13	Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy and Behavior, 2019, 101, 106296.	1.7	8
14	Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. Academic Emergency Medicine, 2019, 26, 940-943.	1.8	39
15	Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. New England Journal of Medicine, 2019, 381, 2103-2113.	27.0	342
16	Sudden unexpected death in epilepsy in patients treated with brainâ€responsive neurostimulation. Epilepsia, 2018, 59, 555-561.	5.1	53
17	Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled <scp>ROSE</scp> trial. Epilepsia, 2018, 59, 1198-1207.	5.1	83
18	Indications and methodology for videoâ€electroencephalographic studies in the epilepsy monitoring unit. Epilepsia, 2018, 59, 27-36.	5.1	61

NATHAN B FOUNTAIN

#	Article	IF	CITATIONS
19	Visual field defects after radiosurgery versus temporal lobectomy for mesial temporal lobe epilepsy: Findings of the ROSE trial. Seizure: the Journal of the British Epilepsy Association, 2018, 63, 62-67.	2.0	11
20	Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurology, The, 2017, 16, 135-143.	10.2	190
21	Brainâ€responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy. Epilepsia, 2017, 58, 994-1004.	5.1	227
22	Brainâ€responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas. Epilepsia, 2017, 58, 1005-1014.	5.1	182
23	Earlier seizure onset and longer epilepsy duration correlate with the degree of temporal hypometabolism in patients with mesial temporal lobe sclerosis. Epilepsy Research, 2017, 138, 105-109.	1.6	18
24	Circadian and ultradian patterns of epileptiform discharges differ by seizureâ€onset location during longâ€ŧerm ambulatory intracranial monitoring. Epilepsia, 2016, 57, 1495-1502.	5.1	134
25	Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy and Behavior, 2015, 52, 119-127.	1.7	70
26	Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. Annals of Neurology, 2015, 78, 323-328.	5.3	59
27	Lateralization of mesial temporal lobe epilepsy with chronic ambulatory electrocorticography. Epilepsia, 2015, 56, 959-967.	5.1	177
28	Mystical experiences associated with seizures. Religion, Brain and Behavior, 2015, 5, 182-196.	0.7	15
29	Quality improvement in neurology. Neurology, 2015, 84, 1483-1487.	1.1	83
30	Interrater reliability in interpretation of electrocorticographic seizure detections of the responsive neurostimulator. Epilepsia, 2015, 56, 968-971.	5.1	49
31	Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology, 2015, 84, 1017-1025.	1.1	594
32	Out-of-body experiences associated with seizures. Frontiers in Human Neuroscience, 2014, 8, 65.	2.0	14
33	Refractory status epilepticus. Neurology, 2014, 82, 650-651.	1.1	11
34	Twoâ€year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial. Epilepsia, 2014, 55, 432-441.	5.1	520
35	Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy and Behavior, 2014, 41, 164-170.	1.7	43
36	A retrospective observational study of current treatment for generalized convulsive status epilepticus. Epilepsy and Behavior, 2014, 37, 95-99.	1.7	16

NATHAN B FOUNTAIN

#	Article	IF	CITATIONS
37	Update on the use of lacosamide in the treatment of partial-onset seizures. Future Neurology, 2014, 9, 301-312.	0.5	0
38	De novo mutations in epileptic encephalopathies. Nature, 2013, 501, 217-221.	27.8	1,351
39	Standardized database development for EEG epileptiform transient detection: EEGnet scoring system and machine learning analysis. Journal of Neuroscience Methods, 2013, 212, 308-316.	2.5	56
40	Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamideâ€naive patients with partialâ€onset seizures. Epilepsia, 2013, 54, 58-65.	5.1	45
41	Delivering quality care in epilepsy. Current Opinion in Neurology, 2013, 26, 174-178.	3.6	5
42	Patient assessment of physician performance of epilepsy quality-of-care measures. Neurology: Clinical Practice, 2012, 2, 335-342.	1.6	21
43	An unusual presentation of antiâ€Huâ€associated paraneoplastic limbic encephalitis. Developmental Medicine and Child Neurology, 2012, 54, 863-866.	2.1	20
44	CHOOSING AMONG ANTIEPILEPTIC DRUGS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 121-135.	0.8	8
45	Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia, 2010, 51, 899-908.	5.1	1,494
46	Essential services, personnel, and facilities in specialized epilepsy centers—Revised 2010 guidelines. Epilepsia, 2010, 51, 2322-2333.	5.1	184
47	Examining the Clinical Utility of Lacosamide. CNS Drugs, 2010, 24, 1041-1054.	5.9	77
48	A Pregnant Pause to Consider Teratogenicity of Topiramate. Epilepsy Currents, 2009, 9, 36-38.	0.8	17
49	Should Levetiracetam Replace Phenytoin for Seizure Prophylaxis after Neurosurgery?. Epilepsy Currents, 2009, 9, 71-72.	0.8	15
50	Intravenous lacosamide as replacement for oral lacosamide in patients with partialâ€onset seizures. Epilepsia, 2008, 49, 418-424.	5.1	111
51	Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Research, 2007, 74, 60-69.	1.6	44
52	Epilepsy in Football Players and Other Land-based Contact or Collision Sport Athletes. Current Sports Medicine Reports, 2004, 3, 284-288.	1.2	18
53	Standardized mental status testing for nonconvulsive status epilepticus. American Journal of Electroneurodiagnostic Technology, 2004, 44, 199-201.	0.2	0
54	Epilepsy and athletics. Clinics in Sports Medicine, 2003, 22, 605-616.	1.8	40

NATHAN B FOUNTAIN

#	Article	IF	CITATIONS
55	Clinical Correlation of Occipital Intermittent Rhythmic Delta Activity. Journal of Clinical Neurophysiology, 2003, 20, 35-41.	1.7	36
56	Quality of life outcome is associated with cessation rather than reduction of psychogenic nonepileptic seizures. Epilepsy and Behavior, 2002, 3, 455-459.	1.7	47
57	Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open-label Trial. Epilepsia, 2002, 43, 518-524.	5.1	150
58	Effects of Benzodiazepines on Triphasic Waves. Journal of Clinical Neurophysiology, 2001, 18, 345-352.	1.7	111
59	Pharmacokinetic Study of Levetiracetam in Children. Epilepsia, 2001, 42, 1574-1579.	5.1	148
60	Status Epilepticus: Risk Factors and Complications. Epilepsia, 2000, 41, S23-S30.	5.1	226
61	Functional anatomy of limbic epilepsy: a proposal for central synchronization of a diffusely hyperexcitable network. Epilepsy Research, 1998, 32, 194-205.	1.6	162
62	Responses of Deep Entorhinal Cortex are Epileptiform in an Electrogenic Rat Model of Chronic Temporal Lobe Epilepsy. Journal of Neurophysiology, 1998, 80, 230-240.	1.8	47
63	Sleep Deprivation Activates Epileptiform Discharges Independent of the Activating Effects of Sleep. Journal of Clinical Neurophysiology, 1998, 15, 69-75.	1.7	157